The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches
Open accessAbstract
Interplay among immune activation and cancer pathogenesis provides the framework for a novel subspecialty known as immunooncology. In the rapidly evolving field of immunooncology, understanding the tumor-specific immune response enhances understanding of cancer resistance. This review highlights the fundamentals of incorporating precision medicine to discover new immune biomarkers and predictive signatures. Using a personalized approach may have a significant, positive impact on the use of oncolytics to better guide safer and more effective therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 4×
“Through these studies, Wol-chok and colleagues confirmed that Ipilimumab’s targeted effect, efficacy, and outcome are better when simultaneously given with Nivolumab [75].”
InfluentialCancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Glycosylation in cancer: mechanisms and clinical implications
Pinho, S. S., & Reis, C. A. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3982 · Cited by 3,083
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Sharma, S., Kelly, T. K., & Jones, P. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp220 · Cited by 2,637
Overview of the immune response
Chaplin, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.12.980 · Cited by 2,235
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
Complement and its role in innate and adaptive immune responses
Dunkelberger, J. R., & Song, W.-C. (2010) · Cell Research · doi:10.1038/cr.2009.139 · Cited by 1,932
Structure and function of immunoglobulins
Schroeder, H. W., & Cavacini, L. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.046 · Cited by 1,905
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
DNA methylation in cancer: too much, but also too little
Ehrlich, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205651 · Cited by 1,538
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Nishida, N., Yano, H., Nishida, T., Kamura, T., & Kojiro, M. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.213 · Cited by 1,434
CD4 + T Cells: Differentiation and Functions
Luckheeram, R. V., Zhou, R., Verma, A. D., & Xia, B. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/925135 · Cited by 1,381
Systemic effects of local radiotherapy
Formenti, S. C., & Demaria, S. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70082-8 · Cited by 1,021
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
Historical insights into cytokines
Dinarello, C. A. (2007) · European Journal of Immunology · doi:10.1002/eji.200737772 · Cited by 926
Crossing the endothelial barrier during metastasis
Reymond, N., d'Água, B. B., & Ridley, A. J. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3628 · Cited by 922
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Cheever, M. A., & Higano, C. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3126 · Cited by 780
Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2360 · Cited by 758
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.003 · Cited by 752
Tumor-Associated Neutrophils: New Targets for Cancer Therapy
Gregory, A. D., & McGarry Houghton, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2583 · Cited by 707
NK cells and cancer immunosurveillance
Waldhauer, I., & Steinle, A. (2008) · Oncogene · doi:10.1038/onc.2008.267 · Cited by 682
The IL-2 Receptor Complex: Its Structure, Function, and Target Genes
Minami, Y., Kono, T., Miyazaki, T., & Taniguchi, T. (1993) · Annual Review of Immunology · doi:10.1146/annurev.iy.11.040193.001333 · Cited by 604
An introduction to immunology and immunopathology
Warrington, R., Watson, W., Kim, H. L., & Antonetti, F. R. (2011) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-7-s1-s1 · Cited by 596
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
Wang, K., Wei, G., & Liu, D. (2012) · Experimental Hematology & Oncology · doi:10.1186/2162-3619-1-36 · Cited by 562
IL-2, Regulatory T Cells, and Tolerance
Nelson, B. H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.3983 · Cited by 556
Shi, Y., Liu, C. H., Roberts, A. I., Das, J., Xu, G., Ren, G., Zhang, Y., Zhang, L., Yuan, Z. R., Tan, H. S. W., et al. (2006) · Cell Research · doi:10.1038/sj.cr.7310017 · Cited by 547
Big opportunities for small molecules in immuno-oncology
Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 471
Genetic Susceptibility to Cancer: The Role of Polymorphisms in Candidate Genes
Dong, L. M., Potter, J. D., White, E., Ulrich, C. M., Cardon, L. R., & Peters, U. (2008) · JAMA · doi:10.1001/jama.299.20.2423 · Cited by 461
Tögel, F., Isaac, J., Hu, Z., Weiss, K., & Westenfelder, C. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00275.x · Cited by 373
Przepiorka, D., Ko, C.-W., Deisseroth, A., Yancey, C. L., Candau-Chacon, R., Chiu, H.-J., Gehrke, B. J., Gomez-Broughton, C., Kane, R. C., Kirshner, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0612 · Cited by 373
Sharpe, A. H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00784.x · Cited by 357
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
Contardi, E., Palmisano, G. L., Tazzari, P. L., Martelli, A. M., Falà, F., Fabbi, M., Kato, T., Lucarelli, E., Donati, D., Polito, L., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21155 · Cited by 324
Chapter 8 The Role of NKT Cells in Tumor Immunity
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)00408-9 · Cited by 316
Monoclonal antibodies for cancer immunotherapy
Weiner, L. M., Dhodapkar, M. V., & Ferrone, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60251-8 · Cited by 307
Chien, Y.-H., Jores, R., & Crowley, M. P. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.511 · Cited by 283
Tracing the cellular origin of cancer
Blanpain, C. (2013) · Nature Cell Biology · doi:10.1038/ncb2657 · Cited by 276
The Role of Complement in Tumor Growth
Pio, R., Corrales, L., & Lambris, J. D. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-5915-6_11 · Cited by 198
Duran‐Struuck, R., & Dysko, R. C. (2009) · PubMed Central · Cited by 175
Natural killer cells remember: An evolutionary bridge between innate and adaptive immunity?
Sun, J. C., & Lanier, L. L. (2009) · European Journal of Immunology · doi:10.1002/eji.200939435 · Cited by 168
Combination immunotherapy approaches
Drake, C. G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds262 · Cited by 168
DNA Methylation and Cancer Development: Molecular Mechanism
Akhavan‐Niaki, H., & Samadani, A. A. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9555-2 · Cited by 158
Podojil, J. R., & Miller, S. D. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00773.x · Cited by 157
Molecular‐targeted agents combination therapy for cancer: Developments and potentials
Li, F., Zhao, C., & Wang, L. (2013) · International Journal of Cancer · doi:10.1002/ijc.28261 · Cited by 140
TLR7 induces anergy in human CD4+ T cells
Dominguez‐Villar, M., Gautron, A.-S., de Marcken, M., Keller, M. J., & Hafler, D. A. (2014) · Nature Immunology · doi:10.1038/ni.3036 · Cited by 139
Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy
Mandal, R., & Chan, T. A.-T. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0146 · Cited by 126
Complement Activation Pathways: A Bridge between Innate and Adaptive Immune Responses in Asthma
Wills-Karp, M. A. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200704-046aw · Cited by 122
Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells
Uy, G. L., Rettig, M. P., & Cashen, A. F. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.11.1797 · Cited by 113
Complement regulation of T cell immunity
Kwan, W.-H., van der Touw, W., & Heeger, P. S. (2012) · Immunologic Research · doi:10.1007/s12026-012-8327-1 · Cited by 106
Vaccines to Prevent Infections by Oncoviruses
Schiller, J. T., & Lowy, D. R. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134019 · Cited by 101
Primer on tumor immunology and cancer immunotherapy
Harris, T. J., & Drake, C. G. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-12 · Cited by 86
Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment
Aris, M., & Barrio, M. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00046 · Cited by 85
Multiple Roles of CD4 and CD8 in T Cell Activation
Koretzky, G. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1090076 · Cited by 79
Targeting gamma delta T cells for cancer immunotherapy: bench to bedside.
Gogoi, D., & Chiplunkar, S. V. (2013) · Europe PMC (PubMed Central) · Cited by 56
Hoos, A., & Britten, C. M. (2012) · OncoImmunology · doi:10.4161/onci.19268 · Cited by 53
Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.
Magee, M. S., & Snook, A. E. (2014) · PubMed · Cited by 48
Granulocyte Macrophage Colony-Stimulating Factor: Current Practice and Novel Approaches
Buchsel, P. C., Forgey, A., Grape, F. B., & Hamann, S. S. (2002) · Clinical journal of oncology nursing · doi:10.1188/02.cjon.198-205 · Cited by 39
Immunotherapy: Making the case for precision medicine
Bluestone, J. A., & Tang, Q. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa9846 · Cited by 19
Cited by
Miao, Y., Zhang, Q., Lei, Q., Luo, M., Xie, G., Wang, H., & Guo, A. (2020) · Advanced Science · doi:10.1002/advs.201902880 · Cited by 973
Immune function and micronutrient requirements change over the life course
Maggini, S., Pierre, A., & Calder, P. C. (2018) · Nutrients · doi:10.3390/nu10101531 · Cited by 710
Neoantigen: A New Breakthrough in Tumor Immunotherapy
Zhang, Z., Lu, M., Qin, Y., Gao, W., Tao, L., Su, W., & Zhong, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672356 · Cited by 284
Fu, Q., Chen, N., Ge, C., Li, R., Li, Z., Zeng, B., Li, C., Wang, Y., Xue, Y., Song, X., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1593806 · Cited by 274
Metadata
- Authors
- Pandya, P. H., Murray, M. E., Pollok, K. E., & Renbarger, J. L.
- Venue
- Journal of Immunology Research
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-13
- ISSN
- 2314-7156 (ISSN-L)
- 2314-8861
- OpenAlex
- W2566704745
- Cited by
- 259
- References
- 68
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.